Ramon San Miguel
Overview
Explore the profile of Ramon San Miguel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roncal-Belzunce V, Gutierrez-Valencia M, Cedeno-Veloz B, San Miguel R, Marin-Epelde I, Galbete A, et al.
Aging Med (Milton)
. 2025 Feb;
8(1):e70001.
PMID: 39968007
Objectives: The increase in polypharmacy among older adults increases the risk of drug-related problems, making multidisciplinary interventions essential. This study evaluated the impact of a multidisciplinary polypharmacy consultation on medication...
2.
Cost-Utility Analysis of Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms
Capdevila F, Insausti I, San Miguel R, Sanchez-Iriso E, Montesino M
Cardiovasc Intervent Radiol
. 2023 May;
46(8):1025-1035.
PMID: 37142802
Purpose: To perform a post hoc cost-utility analysis of a randomized controlled clinical trial comparing prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP) in patients with lower...
3.
Burgui C, San Miguel R, Goni-Esarte S, Juanbeltz R, Uriz-Otano J, Reparaz J, et al.
Postgrad Med
. 2022 Oct;
135(4):352-360.
PMID: 36305320
Objectives: Second-generation direct-acting antivirals (DAAs) have shown high efficacy in the treatment of chronic hepatitis C virus (HCV) infections in clinical trials. This study aimed to estimate the effectiveness in...
4.
Tejada D, Juanbeltz R, Rivero M, San Miguel R, Capdevila F, Beloqui J, et al.
PLoS One
. 2022 Apr;
17(4):e0267283.
PMID: 35482685
Background: There is currently much uncertainty regarding the most optimal treatment for COVID-19. This study analyze the change in the clinical condition of patients hospitalized for severe COVID-19 pneumonia and...
5.
Burgui C, Martin C, Juanbeltz R, San Miguel R, Martinez-Baz I, Zozaya J, et al.
Rev Esp Enferm Dig
. 2020 Jun;
112(7):525-531.
PMID: 32515981
Background: hepatitis C virus (HCV) antibody tests have been performed since the 90s, although HCV-RNA (viral load) determination was not always performed. Some of these patients may be actively infected...
6.
Fontela C, Aguinaga A, Moreno-Iribas C, Reparaz J, Rivero M, Gracia M, et al.
Sci Rep
. 2020 Jun;
10(1):8922.
PMID: 32488053
Combination antiretroviral therapy reduces mortality of HIV-infected persons. In Spain, where this therapy is widely available, we aim to evaluate mortality trends and causes of death in HIV-infected adults, and...
7.
Goni Esarte S, Juanbeltz R, Martinez-Baz I, Castilla J, San Miguel R, Herrero J, et al.
Rev Esp Enferm Dig
. 2019 May;
111(6):445-452.
PMID: 31066286
Background And Aim: new direct-acting antivirals (DAAs) achieve high and sustained virological response (SVR) rates, although the long-term effect on patient health-related quality of life (HRQoL) is unknown. This study...
8.
Juanbeltz R, Castilla J, Martinez-Baz I, OLeary A, Sarobe M, San Miguel R
Qual Life Res
. 2019 Jan;
28(6):1477-1484.
PMID: 30666549
Purpose: To compare health-related quality of life (HRQoL) between hepatitis C patients who achieve sustained virological response (SVR) to direct-acting antivirals and a sex- and age-paired sample of the general...
9.
Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain
Juanbeltz R, Perez-Garcia A, Aguinaga A, Martinez-Baz I, Casado I, Burgui C, et al.
PLoS One
. 2018 Dec;
13(12):e0208554.
PMID: 30513107
Background: The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress...
10.
Juanbeltz R, Martinez-Baz I, San Miguel R, Goni-Esarte S, Cabases J, Castilla J
PLoS One
. 2018 Oct;
13(10):e0205277.
PMID: 30300395
Background: Direct-acting antivirals (DAA) have demonstrated high efficacy to achieve sustained virological response (SVR) in chronic hepatitis C patients. We aim to assess the change in health-related quality of life...